Study on Indomethacin-responsive Headaches

May 27, 2019 updated by: Anne Ducros

Non Interventional Study on Indomethacin-responsive Headaches

Description of modalities concerning the patient care of headaches sensible to indometacine.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Description of clinical profile, treatment of crisis and background treatment

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 98 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patient sufffuring from headaches or migraine and who is receiving Indometacine

Description

Inclusion Criteria:

  • patient with a diagnosis of migraine with or without aura, or trigemino-autosomic headaches or other primary headaches
  • patient who are taking indometacine
  • patient with written consent form

Exclusion Criteria:

  • patient under 18 years
  • pregnant woman or breastfeeding patient
  • patient who refuses to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Description of headaches sensible to indometacine
Time Frame: 24 monthes
Description of the clinical cases with headaches sensible to indometacine according to the type of headaches.
24 monthes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Anne Ducros

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2019

Primary Completion (Anticipated)

June 1, 2020

Study Completion (Anticipated)

June 1, 2021

Study Registration Dates

First Submitted

May 27, 2019

First Submitted That Met QC Criteria

May 27, 2019

First Posted (Actual)

May 30, 2019

Study Record Updates

Last Update Posted (Actual)

May 30, 2019

Last Update Submitted That Met QC Criteria

May 27, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019-A00406-51

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Headache, Migraine

Clinical Trials on Indometacin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe